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“Weiss nix, kann aber alles erklären.”      (Hanns Dieter Hüsch) 
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ABSTRACT 
Amyloid is associated with both pathological protein deposits and the formation of 
functional protein structures. Therefore, several strategies have evolved to control the 
formation or inhibition of amyloid in vivo. In this thesis, three separate systems were 
investigated in which amyloidogenic protein segments are coupled to regulatory 
elements that prevent or promote fibrillation. We describe the molecular mechanism for 
how (a) a propeptide segment prevents the uncontrolled aggregation of the mature 
peptide, (b) a chaperone domain inhibits amyloid formation, and (c) a pH-dependent 
relay controls protein assembly. For this purpose, mass spectrometry (MS)-based 
approaches to structural biology were applied and extended, involving gas phase 
interaction studies and hydrogen/deuterium exchange MS. 
(a) Proinsulin C-peptide is beneficial for the preservation of insulin activity. We show 
that C-peptide interferes with insulin amyloid fibril formation at low pH and how 
conserved glutamate residues in C-peptide mediate reversible co-precipitation with 
insulin. A mechanism is proposed for how the balance between zinc and C-peptide 
mediates sorting of insulin into slow acting and rapid acting forms inside the secretory 
granules of the pancreatic β-cells, which potentially links C-peptide to diabetes type 1 
and 2. 
(b) Lung surfactant protein C (SP-C) is a highly amyloidogenic transmembrane 
polypeptide that controls surface tension in the alveolar phospholipid bilayer. Its 
proprotein includes a conserved chaperone domain termed BRICHOS, which is also 
associated with neurodegenerative disorders. It is shown here how BRICHOS and its 
N-terminal linker recognize hydrophobic residues and trap the SP-C segment in a β-
hairpin conformation to prevent amyloid formation.  
(c) Spider silk is synthesized as a highly soluble protein that assembles into silk in a 
pH-dependent fashion. It is shown that the spider silk protein N-terminal (NT) domain 
dimerizes at the same pH interval that triggers silk assembly, and we define the 
associated structural changes. Furthermore, the use of the NT domain as a solubility 
tag for the expression of aggregation-prone proteins is demonstrated. 
In summary, we have determined the molecular basis for three distinct mechanisms by 
which fibril formation is controlled through autoregulatory elements and provide insights 
into nature’s strategies to control amyloid formation and prevention. Based on these 
findings, we can now make conclusions about nature’s handling of amyloidogenic 
proteins and their function in general. 
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1 PREFACE 
 
This thesis summarizes research conducted over the years 2008 - 2012 at the 
Department of Medical Biochemistry and Biophysics (MBB), Karolinska Institutet (KI), a 
department devoted to the study of molecular mechanisms of human disease. 
The work combines research on diabetes, neurodegenerative disease, and spider silk 
formation, with emphasis on application and development of mass spectrometrical 
methods in protein structure analysis for conclusions about amyloidogenic proteins in 
general. The thesis contains a wide spread of methods, structures, and diseases, 
which was made possible through the fruitful collaboration of my three supervisors, 
Professors Hans Jörnvall, Tomas Bergman, and Jan Johansson. As indicated by the 
author list for each paper included in this thesis, not all publications are based on my 
work primarily, but I was able to make significant contributions to each thanks to the 
versatility and robustness of mass spectrometry-based protein structure analysis. 
Accordingly, I have focused on my contributions to the publications, and only the 
corresponding methods are included in the Methodology section. However, I was 
always involved in discussions of key results and in the preparation of the final 
manuscripts, and have included all studies to provide a complete picture. 
At the start of my Ph.D. studies, we designed a three-phase project: the first phase 
aimed to establish and extend Hydrogen/Deuterium Exchange (HDX) Mass 
Spectrometry (MS), the second phase to apply MS-based methods to investigate the 
chaperone activity of the BRICHOS domain on lung surfactant protein C (SP-C), and 
the third phase to broaden the HDX-MS-based investigations to include other amyloid-
related proteins. 
Phase one and two resulted in four publications (Paper III and Papers VII, VIII, and IX, 
respectively). However, already at the end of the first phase, the opportunity arose to 
apply MS to study the pH-dependent assembly of spider silk, which is under 
investigation in the group of Jan Johansson. My involvement resulted in an MS-based 
publication (Paper X) and allowed me to contribute mass spectrometrical analyses 
during the follow-up investigations (Papers XI and XII). Since Hans Jörnvall has a long-
standing interest in the biological role of proinsulin C-peptide and its chaperone-like 
effect on mature insulin, he suggested to further broaden the scope of this work to 
clarify the nature of this interaction. Our findings and the resulting implications are 
summarized in Papers IV, V, and VI. 
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During the course of my studies, it became obvious that the ability to regulate amyloid 
formation is a common feature of these three protein systems, either in its prevention, 
as exemplified by insulin and SP-C biogenesis, or its controlled occurrence, as in 
spider silk assembly. C-peptide, the BRICHOS domain, and the spidroin N-terminal 
domain all represent controlling elements in the (pro)protein and act as an intrinsic 
modulator of amyloid formation. This primed us to search the literature for more 
examples of self-regulating amyloid. We have summarized the well-characterized 
systems in an article that places the results presented in this thesis in the context of the 
current state of amyloid research and concludes this thesis (Paper XIII). 
Furthermore, I have chosen to include two overview articles as an introduction: a 
summary of the nature of amyloid and its prevention (Paper I) and a description of 
mass spectrometry as a protein structure analysis tool (Paper II). 
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2 INTRODUCTION 
 
2.1 STRUCTURAL FEATURES OF AMYLOID (PAPER I) 
 
2.1.1 What is amyloid? 
A long-standing dogma of molecular biology has stated that for each polypeptide chain, 
a specific conformation exists that defines its lowest energy structure and represents its 
native state. The universal validity of this hypothesis, however, has been challenged by 
a discovery that precedes it by more than 300 years. 
In 1639, the Italian physician Nicolaus Fontanus reported a wax-like abnormality in the 
spleen of a patient with liver failure. In 1854, Rudolf Virchow introduced the term 
“amyloid” for its macroscopic resemblance to an amylaceous (i.e. starchy) plant 
constituent, but noted that “only when we have discovered the means of isolating the 
amyloid substance shall we be able to come to any definite conclusion with regard to 
its nature” [1]. 
While reports of similar pathological abnormalities were subsequently linked to a 
variety of diseases, it was not until 1859 that protein was suggested to be constituent 
and, in 1931, was identified as the primary component of amyloid. Since then, 
advances in the use of chemical dyes, electron microscopy (EM) and, finally, high 
resolution protein structure analysis have led to the realization that amyloid represents 
a distinct class of (mis)folded proteins [2]. 
The modern biophysical definition states that proteins in the amyloid state exhibit green 
fluorescence when stained with Thioflavin T (ThT), as well as green birefringence when 
stained with Congo Red and viewed under polarized light. In EM, amyloid appears as 
straight, unbranched fibers with diameters between 6 and 12 nm. X-ray diffraction 
shows a pattern characteristic for β-sheets that run perpendicular to the fibril axis. The 
β-sheet motif is repeated periodically by thousands and thousands of stacked subunits 
that are usually composed of a single peptide each (Figure 1) [3]. Structural 
characteristics as well as strategies to prevent amyloid formation, outlined below, are 
discussed in Paper I. 
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Figure 1. Structural organization of pathogenic amyloid. Amyloid plaques as observed in the brain of AD 
patients (left panel) are composed of individual fibrils, as visualized by EM (middle panel). The molecular 
structure of such fibrils consists of regularly stacked β-sheets from multiple copies of a single protein or 
peptide species (right panel). Scale bars represent 50 µM in the plaque and 100 nm in the EM 
micrograph. Reproduced from Paper I. 
 
2.1.2 Molecular structure and sequence determinants of amyloid fibrils 
Even though amyloid fibrils possess such a highly ordered nature, insights into their 
molecular structure are notoriously difficult to obtain, and to date a solid-state NMR 
structure [4] as well as a small variety of crystal structures of nanofibers and 3D- 
crystals [5] exist.  
While it has long been a matter of discussion whether the ability to form amyloid fibrils 
is a general property of the protein backbone, only a minor subset of proteins can form 
amyloid in vivo. This means that some proteins contain unprotected amyloid formation 
“hotspots” in their sequence that allows amyloid formation under physiological 
conditions [6]. On the other hand, the ability to form amyloid fibrils is a general feature 
but controlled to occur only under very specific circumstances, such as presence at 
high concentrations, altered pH, and together with destabilizing agents [7]. 
The suggestion that some sequences are more prone to aggregation than others is 
supported by studies on fragments of amyloid disease-associated proteins. Amyloid-
forming sequence motifs have been found e.g. in insulin, the Alzheimer’s Disease 
(AD)-related Amyloid β peptide (Aβ), the yeast Sup35 prion, prion protein, and islet 
amyloid polypeptide. Crystal structures derived from such short model peptides exhibit 
the expected parallel or antiparallel β-strand register. Surprisingly, some of the short 
model peptides have been found to form very densely packed “steric zipper” structures, 
in which sidechains and backbone amides form a tight interaction that excludes water 
from the interface [5, 8, 9]. 
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However, no obvious sequence homology can be derived from these motifs, and 
amyloid peptide structures have been reported that do not feature steric zipper motifs 
[10]. Some structures contain tight interactions between aromatic sidechains instead, 
which have been suggested to mediate amyloid peptide assembly through stacking of 
pi-bonds [11, 12]. While several model peptides contain aromatic residues, it has been 
demonstrated that they can be replaced by non-aromatic, hydrophobic amino acids 
without losing the ability to form amyloid fibrils, as long as a balance of negative and 
positive sidechains is maintained [13]. 
Several prediction strategies have been described to identify amyloid-forming 
sequences, based on their content of β-sheet stabilizing or de-stabilizing residues [14, 
15], the ability of the sidechains to pack into a β-sheet structure [16], or by assignment 
of an “aggregation score” for each amino acid based on its occurrence in α-helices and 
β-sheets, hydrophobicity, and charge [17]. 
A different approach is the identification of stretches in amyloid-forming proteins that 
form α-helices but have a higher propensity to form β-sheets [18]. A prominent 
example of such a “frustrated” or discordant helix is the lung surfactant protein C (SP-
C), the mature form of which contains a 12-residue poly-valine stretch that forms a 
transmembrane helix when inserted into the lung surfactant phospholipid bilayer [19], 
but is thermodynamically unstable and forms β-sheet aggregates in vitro [20]. 
A “reverse” example of sequence discordance in β-sheet conversion is the aggregation 
of arthropod major ampullate silk proteins (MaSp), the main constituents of spider 
dragline silk (see section 2.5). MaSp are mostly unstructured or helical in solution [21] 
and have a high α-helix propensity, but form β-sheet crystalline blocks during silk 
assembly [22, 23] and give the assembled spider silk amyloid fibril-like properties [24]. 
 
2.1.3 Mutations, miscleavages, transmission: Pathogenic amyloid 
Most amyloid deposits formed in vivo are disease-associated. As of 2012, 28 proteins 
have been described to form amyloid fibrils that are linked to human disease and can 
occur either as accompanying symptom or molecular cause of the disease [25]. The 
reasons for conversion of a folded protein into amyloid fibrils are only partially known 
and include mutations, cleavage, and interactions with other misfolded proteins. 
Mutations can cause the generation of amyloidogenic species, as in the familial Danish 
and British Dementias (FDD and FBD), where a stop-codon mutation extends the 23-
residue C-terminal signal peptide of the Bri2 gene product to 34 residues and strongly 
increases its aggregation propensity [26, 27].  
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(Mis)Cleavage of precursor peptides can also generate amyloid-forming products, as 
exemplified by the amyloid β precursor protein (APP), which gives rise to Aβ1-40 and 
Aβ1-42 as well as the less toxic Aβ1-39 peptides. Formation of the toxic Aβ1-42 oligomers 
and subsequent aggregation into amyloid fibrils are thought to be responsible for AD. 
A special case is the self-propagating misfolding mechanism that is observed in 
spongiform encephalopathies caused by aggregated prion protein (PrPSC). Here, a 
small fraction of misfolded PrP can trigger conversion of the folded cellular PrPC into 
the pathogenic, amyloid-forming PrPSC form, which makes PrPSC an infectious agent 
[28]. Interestingly, similar behavior has recently been reported for the Aβ peptide, 
which, when injected in amyloid form, can induce β-amyloidosis in mice [29]. Several 
additional factors have been described to influence amyloid formation in vivo, such as 
protein concentration, e.g. in localized insulin amyloidosis in diabetic patients, where 
high local insulin concentrations at the site of repeated injections give rise to amyloid 
deposits composed of misfolded insulin [30]. Similarly, post-translational modifications, 
e.g. in neurofibrillar tangles formed by hyperphosphorylated tau protein, are thought to 
contribute to AD [31]. Most proteins associated with protein aggregation diseases have 
been found to form amyloid fibrils also in vitro, such as mutant ataxins (Polyglutamine 
diseases, PolyQ) [32] and α-synuclein (Parkinson’s Disease, PD) [33]. In these cases, 
in vivo occurrence of plaques with amyloid properties might have escaped detection, or 
do not share all known characteristics of amyloid deposits [25]. 
 
2.2 CONTROL OF AMYLOID FORMATION IN VIVO 
 
2.2.1 Molecular chaperones in protein aggregation diseases 
Common to most amyloid-forming proteins is the existence of aggregation-prone 
sequence elements. Hence, stabilization of such motifs by molecular chaperones 
represents a possible approach to the prevention of amyloid formation. 
Two approaches have successfully demonstrated the relation between molecular 
chaperones and protein aggregation diseases: Expression of molecular chaperones in 
protein aggregation disease models, and proteomics- and immunohistochemistry-
based characterization of the content of protein aggregates isolated from patient 
material. 
Both approaches have identified chaperones of the heat shock protein (HSP) families 
as potential modulators of protein aggregation. In the case of co-expression of 
molecular chaperones with protein aggregation disease-related genes, it was found 
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that HSP70 rescues cultured neurons expressing Aβ1-42 by reducing aggregate load 
[34], and similarly promotes α-synuclein refolding in a cell culture model of PD [35]. 
Neuroprotective effects of HSPs have been demonstrated in Drosophila PD [36] and 
PolyQ disease [37, 38] models. Subsequently, an HSP-related pathway was identified 
as component of Aβ proteostasis in a C.elegans model of AD [39]. Pharmacological 
induction of HSP expression has also been shown to delay the progression of 
amyotrophic lateral sclerosis (ALS) in a mouse model [40]. Furthermore, analyses of 
patient-derived protein deposits have confirmed the presence of HSPs in aggregates 
from AD, PD, HD, PolyQ diseases, Lewy Body dementia, and ALS (summarized in 
[41]). This suggests that molecular chaperones can be effectively used to combat 
pathogenic protein aggregation. 
However, since the latter examples lack the biochemical hallmarks of amyloid disease 
[25], the only reported instance of chaperone activity against established pathogenic 
amyloid is the connection between HSPs and Aβ aggregation in AD, and to date no 
case of in vivo amyloid formation due to malfunction of a non-specific chaperone has 
been described. 
 
2.2.2 The emerging concept of functional amyloid 
While amyloid formation is predominantly seen as a hallmark of protein aggregation 
disease, a growing body of evidence suggests that certain forms of amyloid can serve 
specific biological functions. The first “functional amyloids”, as they were termed, were 
reported to form fimbriae of gram-negative E. coli [42]. These fimbriae, which serve in 
bacterial surface adhesion, are composed of six proteins of the Csg family and share 
features of amyloid fibrils such as morphological similarity and ThT and Congo Red 
stainability [43]. A second bacterial amyloid, but with a different biological function, was 
detected to be the Chaplin proteins that aid spore dispersal [44]. Subsequently, several 
additional bacterial amyloids with roles in biofilm formation, surface attachment, and 
pore formation were described (reviewed in [45]). 
The first eukaryotic example was the yeast Sup35 prion: In soluble form, it serves as 
DNA transcription factor, while its ability to assemble into amyloid fibrils allows its 
transmission (in active or inactive form) to the next generation as a non-genetic 
element of inheritance [46]. 
In recent years, two reports have described functional amyloid in humans: melanin 
biosynthesis was found to require amyloid fibril formation by the Pmel17 protein. 
Pmel17 amyloid functions as scaffold for the assembly of melanin polymers while 
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preventing the release of toxic melanin precursors [47]. Furthermore, it was reported 
that 31 different human peptide hormones were capable of forming non-toxic amyloid 
assemblies in secretory granules but can be released in biologically active form [48]. 
Another type of protein assembly with amyloid-like properties is the family of arthropod 
silks, i.e. spider silk. Of the different spider silks that fulfill diverse functions and 
possess a variety of chemical and physical properties, the spider dragline silk is the 
most studied. Assembly of the aggregation-prone regions of MaSp1 (that represent the 
main constituent of dragline silk) in the duct of the spider silk glands converts the 
soluble “storage” form into the β-sheet silk form [23]. 
 
2.2.3 Regulatory strategies to control amyloid formation 
Due to the extreme stability and potentially toxic nature of amyloid, the apparently 
beneficial presence of amyloidogenic proteins and peptides requires sophisticated 
control mechanisms that go beyond those provided by most molecular chaperones. 
Three basic strategies have evolved to regulate the formation of functional amyloid: 
(1) Specialized chaperones regulate the assembly of prions into amyloid fibrils in 
yeast. The chaperone HSP104 represents one of few known examples for specialized 
amyloid chaperoning systems and is unique in its ability to disassemble amyloid fibers 
composed of the yeast prion protein Sup35 [49]. Proinsulin C-peptide can be 
considered an example of a chaperoning domain as it blocks the conversion of insulin 
into amyloid fibrils (see section 2.3). Another example is the proSP-C BRICHOS 
domain, which has a chaperoning function that prevents the formation of pathogenic 
amyloid, but is also an auto-regulatory element (see section 2.4). 
(2) Regulatory domains have been identified in functional amyloids, such as the yeast 
HET-s and HET-S prions, as well as in the proteins that form spider silk. Here, 
conformational changes in “switch domains” trigger or prevent aggregation. Spider silk 
spidroins contain N- and C-terminal non-repetitive domains, which control fiber 
assembly by responding to pulling forces during spinning as well as changes in salt 
concentration and pH along the spinning duct ([50] and section 2.5). 
(3) Selective precursor processing has been suggested to play a major role in the 
assembly of functional amyloids such as the assembly of peptide hormone amyloid, 
where cleavage of proforms is thought to generate more or less amyloidogenic species 
[48]. C-peptide still affects insulin amyloid formation after excision from proinsulin 
during insulin processing (see section 2.3) and thus provides evidence that selective 
processing of blocking elements can be used to control amyloid formation in vivo. 
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2.3 PROINSULIN PROCESSING AND AMYLOID FORMATION 
 
2.3.1 Insulin biogenesis and processing 
Insulin is a 51-residue peptide hormone that promotes glucose uptake. Type-I diabetes 
is caused by insulin deficiency which can be treated by administration of recombinant 
insulin through subcutaneous injection. The mature form is composed of two mostly 
helical polypeptide chains linked by two inter- and a single intramolecular disulfide 
bridge [51]. Its precursor proinsulin is produced in the islets of Langerhans [52]. 
Subsequent cleavage by type-I and –II endopeptidases releases mature insulin and the 
31-residue C-peptide, which is co-secreted with insulin into the blood stream and has a 
variety of molecular actions [53-55]. C-peptide is largely unstructured in solution except 
for a potential β-turn motif at the C-terminus [56] and can form large oligomers under 
physiological conditions [57]. C-peptide is required for correct folding of proinsulin [58, 
59], which is dependent on the N-terminal acidic residues Glu3, Glu5, and Asp6 [60]. 
Additionally, co-administration of insulin and C-peptide in diabetic rats accelerated 
insulin uptake [61], suggesting that C-peptide has a chaperone-like activity towards 
insulin [62]. 
 
2.3.2 Regulation of insulin amyloid fibril formation 
 At low pH, high concentrations, and elevated temperature, native insulin can assemble 
into amyloid-like fibrils, in which the insulin monomers adopt a cross-β-sheet structure. 
Using mass spectrometry, insulin has been shown to form soluble multimers at low pH 
that are composed of 2, 3, 6 or 12 monomers. These multimers are in rapid equilibrium 
with the monomeric form and increase with increasing insulin concentration [63], but 
retain essentially the same structure as native insulin [64]. However, longer exposure 
to these conditions causes partial unfolding of the monomer [65, 66] and subsequent 
assembly into amyloid-like fibrils composed of 2, 4, and 6 protofilaments [67]. 
Insulin-containing amyloid deposits have been observed in patients with type-I diabetes 
[30]. In these cases, cutaneous local amyloidosis occurs at the site of repeated insulin 
injection in patients using human recombinant and/or porcine insulin [68, 69]. 
Formation of these aggregates is attributed to the high local insulin concentrations as 
well as the increased aggregation propensity of the faster-acting, mostly monomeric 
“LisPro” insulin variant [70]. 
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In order to prevent insulin aggregation and increase bioavailability of the hormone, 
several strategies for inhibition of fibril formation have been tested, including amino 
sugars [71], soluble insulin A and B-chains [72], presence of hydrophilic surfaces and 
solvents [73], small aromatic molecules [74], molecules associated with stress 
reactions [75], and engineered peptides derived from the insulin B-chain [76]. With the 
exception of native A- and B-chain, all of these inhibitors were ineffective unless used 
in >4-fold excess over insulin.  
Interestingly, it has been reported that proinsulin is refractory to insulin fibrillation. While 
it can form β-sheet-rich aggregates under the same conditions as mature insulin, they 
remain morphologically different from insulin fibrils and exhibit significantly extended 
aggregation lag times. It was concluded that proinsulin aggregation is hindered by the 
covalent linkage of insulin A- and B-chain, posing a conformational restraint by 
connecting the N- and C-termini of the insulin polypeptide chains that prevents the 
structural re-arrangement into a cross-β-sheet structure. We hypothesize that the 
absence of insulin amyloid from secretory granules, despite the high local 
concentrations, could also be due to post-cleavage C-peptide effects. 
 
2.4 BRICHOS DOMAINS AND THEIR ROLES IN PROTEIN AGGREGATION 
DISEASES 
 
2.4.1 BRICHOS-containing proteins 
The BRICHOS domain was first identified by Sanchez-Pulido et al. in 2002 [77] from 
multiple sequence alignments. Three families of BRICHOS-containing proteins were 
described: The Bri genes 1-3 (also referred to as ITM2A-C), one homologue of which 
causes familial British dementia [27], Mature Chondromodulin-I, associated with 
chondrosarkoma [78], and the proform of lung surfactant protein C. In a recent 
investigation, more than 300 different proteins in 12 families were found to contain 
BRICHOS domains [79]. The architecture of these proteins is surprisingly similar. 
Common to all is the presence of an N-terminal hydrophobic region that is predicted to 
be helical, a linker region that is predicted to be coiled or helical, the actual BRICHOS 
domain, and a C-terminal segment (Figure 2). Overall sequence conservation is low, 
with only three residues conserved among all BRICHOS domains: D105, C120 and 
C188 (numbering according to human proSP-C). In human proSP-C BRICHOS, the 
cysteines form an intramolecular disulfide bond [80]. Secondary structure predictions of 
all BRICHOS domains suggest that they share a common fold [79]. 
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Figure 2. Organization of BRICHOS-containing proteins. BRICHOS-containing proteins are characterized 
by a transmembrane (TM) segment with an N-terminal signaling peptide, a linker region, and the 
BRICHOS domain. (A) Most BRICHOS-containing proteins feature a C-terminal segment not found in 
proSP-C which is predicted to form β-strands [81]. (B) In case of proSP-C, two strictly conserved 
cysteines form an intramolecular disulfide bond, and the transmembrane region has high β-strand 
propensity.  
 
2.4.2 Biological and structural features of proSP-C 
The transmembrane segment of the proSP-C protein is the lung Surfactant Protein C. 
SP-C lowers the surface tension at the surfactant’s air-water interface and prevents 
collapse of the alveoli during end expiration. Mature SP-C has 35 residues with a 
stretch of 12 valine residues that forms the transmembrane helix (see section 1.2.2). 
SP-C is released by enzymatic cleavage from a 197-residue proform, which, besides 
the mature SP-C sequence, contains the already described linker and a BRICHOS 
domain on the C-terminal side in the endoplasmic reticulum. 
A clue to the function of proSP-C BRICHOS came from the observation that mutations 
in the proSP-C gene SFTPC have been identified as the cause of interstitial lung 
disease (ILD). Intracellular protein aggregates composed of SP-C were found in the 
alveolar type II epithelial cells normally expressing proSP-C for secretion [82]. To date, 
over 50 SFTPC mutations have been described. Interestingly, while most mutations 
that give rise to protein aggregation in other systems are located within the aggregating 
protein itself, the majority of the SFTPC mutations that cause SP-C aggregation are not 
located in the region that comprises mature SP-C, but in the linker and BRICHOS 
domains [83, 84]. Expression of mature SP-C without its linker and BRICHOS 
segments results in virtually undetectable expression levels, but expression in soluble 
form can be elevated by co-expression with the linker and BRICHOS (a construct 
further referred to as CTC, i.e. “C-terminus of proSP-C”) on a separate vector [85]. In 
line with this observation, purified recombinant CTC was found to prevent aggregation 
of peptides with discordant helices prone to amyloid formation, such as polyvaline and 
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the Aβ1-40 peptide, while the mutations that are linked to ILD were found to interfere 
with its anti-amyloid activity [82]. Additionally, binding of purified recombinant CTC to 
decamers composed of a single amino acid covalently linked to cellulose membranes 
showed that CTC can interact with hydrophobic residues that have a high β-sheet 
propensity [86]. In paper VII, we have conducted a mass spectrometric investigation of 
CTC and BRICHOS ligand preferences using gas phase binding to acquire gas phase 
KDs, and CID were used to measure of relative complex stability. 
Using limited proteolysis, it could be shown that the BRICHOS domain is highly 
resistant to tryptic digestion and stabilized by two intramolecular disulfide bonds. 
Binding of the hydrophobic dye 4,4'-Bis(1-anilinonaphthalene 8-sulfonate) (Bis-ANS) 
suggests that a major fraction of the five tyrosines in CTC are located in a hydrophobic 
environment, which could represent a binding site for hydrophobic target peptides [80]. 
In paper VIII, we present the crystal structure of the protease-resistant core of 
BRICHOS as well as the identification of a putative binding site involving the BRICHOS 
domain and the linker region as interaction partners of a polyvaline ligand. We report 
the observation of amyloid deposits in patients with SFTPC mutations in the linker and 
BRICHOS regions, which suggests that aberrant chaperone function can give rise to 
amyloid disease in vivo. 
 
2.4.3 Bri2 and its related familial dementias 
Interestingly, other BRICHOS-containing proteins besides proSP-C are associated with 
protein aggregation disease. Vidal et al. reported amyloid deposits in the brain of 
patients with FDD and FBD [26, 27] which were composed of an extended C-terminal 
peptide from the Bri2 protein that is expressed in several tissues of the brain, but most 
prominently in neurons of the hippocampus and the cerebellum [87]. The wt peptide, 
Bri23, is 23 residues long and, like the 32-residue mutant form (ABri) that is released 
from Bri2 by furin cleavage [88]. Several studies have pointed towards a relationship 
between APP processing and Bri2: Aβ accumulation was found to be inhibited through 
binding of Bri2 to APP [89], and their interaction to be mediated by their respective 
transmembrane domains. Subsequent in vivo studies in a mouse model of AD revealed 
that Bri2 inhibits Aβ accumulation [90]. The link between Bri2 and AD was further 
supported by the observation that amyloid plaques from FDD patients contain Aβ 
peptide, suggesting that ABri32 aggregation occurs in interaction with Aβ [81] and is 
promoted by increased APP processing [91]. Interestingly, the Bri23 peptide can inhibit 
Aβ aggregation in vitro and in vivo [90, 92]. Secondary structure predictions of Bri2 
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indicate a preference for β-sheet conformation in the Bri23 peptide [81], which is 
analogous to the high β-sheet propensity of the transmembrane segment in proSP-C. 
In Paper IX, we present evidence that the Bri2 BRICHOS domain can also interact with 
peptides that have high β-sheet propensity (with Bri23 as the natural target) and 
prevent amyloid formation in a manner similar to the action of CTC. 
 
2.5 SPIDER SILK AS AN AMYLOID-LIKE BIOMATERIAL 
 
2.5.1 Spider silk assembly and structure 
Spider silk is a proteinaceous biomaterial that has evolved to suit a wide variety of 
functions. Besides their superficial morphological similarity, the assembled fiber shares 
a number of characteristics with amyloid fibrils: assembled fibrils can be stained with 
ThT and Congo Red, their secondary structure has been calculated to contain more 
than 70% β-sheet and β-turn motifs, and show X-ray diffraction that indicate a β-sheet 
structure with close inter-sheet packing [24]. Solid-state NMR H/D exchange 
measurements, however, indicate that 50% of the alanine residues which are enriched 
in the repetitive domains of spider silk fibroins (see below) are accessible to water [93], 
indicating that assembled fibers are not completely composed of β-sheets, but contain 
significant amounts of unstructured regions. Molecular mechanics simulations have 
suggested that a balance between semi-extended coil regions and crystalline blocks 
composed of β-sheets could be responsible for the toughness and elasticity of the fiber 
(Figure 3) [94]. This illustrates that the unique mechanical properties of spider silk are 
achieved by controlled assembly of spidroins to contain tough, amyloid-like and elastic, 
disordered segments. 
The most studied variant is dragline silk, which is mainly composed of major ampullate 
spidroin proteins 1 (MaSP1) and 2. They are stored in the major ampullate gland in the 
spider abdomen as a concentrated dope with a protein content of up to 50% (w/v) [95]. 
Interestingly, the proteins maintain a largely α-helical conformation even under these 
extreme conditions [21]. Silk assembly is initiated by pulling of the dope from the major 
ampullate gland’s duct, which simultaneously (a) shifts the pH of the solution from 
approximately 7.0 to below 6.4 [96], (b) reduces the salt content of the dope [97], and 
(c) subjects the dope to pulling forces as it exits the duct [98].  
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Figure 3. Proposed model of spider silk architecture. Assembled spider silk is composed of both β-sheet-
rich and disordered, extended segments, indicating a balance between amyloid-like and flexible regions. 
A single fibroin chain is shown in red. Adapted from Paper XIII. 
 
2.5.2 Architecture of MaSp proteins 
The assembly of silk spidroins into fibers requires a unique arrangement of sequence 
motifs. MaSp proteins have a tripartite organization, with a non-repetitive, conserved N-
terminal domain of ~130 amino acids, a long repetitive region composed of up to 3300 
residues that contains alternating alanine- and glycine-rich segments, and a non-
repetitive, conserved C-terminal domain of ~110 amino acids [99]. The alanine-rich 
segments have been assigned to β-sheet blocks, while specific glycine-containing 
motifs are predominantly found in 310-helices and β-spirals, the occurrence of which 
determines specific mechanical properties of the assembled silk [100]. 
It should be noted that neither glycine nor alanine-rich sequences can be regarded as 
amyloidogenic. Alanine is the amino acid with the highest α-helix propensity and 
therefore likely responsible for the high helix content of the spidroin protein dope. Yet, 
assembly of spider silk fibers converts the highly soluble spidroins to an amyloid-like 
material with β-sheet structure. Studies using truncated spidroin constructs have shown 
that the non-repetitive C-terminal domain is essential for fiber formation [101, 102] and 
can form macroscopic fibers on its own [103]. The high-resolution structure of the 
soluble C-terminal fragment supports the hypothesis that amphipathic helices in the 
entirely helical domain can refold to expose hydrophobic parts that in turn promote silk 
assembly. The C-terminal domain forms a disulfide-linked parallel dimer that has been 
proposed to align the repetitive elements during assembly [104]. 
The N-terminal (NT) non-repetitive domain, on the other hand, despite being the most 
conserved segment of the MaSp proteins, is not required for MaSp1 fiber formation in 
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vitro and has no known homologues in silk-forming proteins from other organisms 
[105]. However, its inclusion in recombinant spidroins promotes their assembly into 
fibrils at pH 6.3, while inhibiting their assembly at high salt concentrations [50]. This 
suggests that the NT domain acts as a molecular switch that senses the pH and salt 
concentration changes during extrusion from the duct and accelerates silk assembly 
accordingly. Its high-resolution crystal structure shows an antiparallel, non-covalent 
dimer of dipolar subunits, each composed of a 5-helix bundle. Replacement of 
conserved residues aspartate 40 (D40) and glutamate 84 (E84) interferes with the pH-
dependent action of the NT domain, further supporting the suggestion that its function 
is charge-dependent [50]. However, how these charge interactions mediate silk 
assembly could not be determined from the crystal structure. 
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3 AIM OF THE THESIS 
 
The aim of this thesis has been to investigate the self-regulatory strategies behind the 
control of amyloid formation in three protein systems: proinsulin processing, the 
biosynthesis of lung surfactant peptide C, and the assembly of spider silk. In order to 
study these mechanisms, we applied mainly gas phase interaction studies and H/D 
exchange mass spectrometry. 
Specifically, we aimed to understand the molecular mechanisms by which 
- proinsulin C-peptide chaperones insulin, 
- the proSP-C BRICHOS domain stabilizes the highly amyloidogenic SP-C  
transmembrane segment, and 
- the N-terminal domain of MaSp1 mediates the pH-dependent assembly of 
spider silk. 
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4 METHODOLOGY 
 
4.1 MASS SPECTROMETRY IN PROTEIN STRUCTURE ANALYSIS (PAPER II) 
 
4.1.1 Why mass spectrometry? 
Since most amyloid-related proteins and peptides are refractory to standard protein 
analysis methods, mass spectrometry can be applied as an alternative for the 
investigation of their structure and function. Two principal strategies were employed: 
gas phase interaction analysis to monitor the formation of non-covalent complexes, and 
hydrogen/deuterium exchange mass spectrometry (HDX-MS) to monitor protein 
structural dynamics in solution. The background to both approaches is summarized in 
Paper II and briefly outlined below. 
 
4.1.2 Protein structure in the gas phase 
The development of electrospray ionization mass spectrometry (ESI-MS) provided soft 
ionization as a means to study intact protein molecules by mass spectrometry . Drops 
from a protein solution are then ionized and evaporated, leaving a charged protein 
species without solvent that is transferred into the vacuum chamber of a quadrupole 
time-of-flight mass spectrometer. In 1991, it was reported that ESI-MS could not only 
produce charged protein species but could also be used to transfer intact protein 
complexes into the gas phase [106]. Over time, evidence has accumulated that it is 
possible for proteins to retain their native fold even after desolvation. Longer exposure 
times to a solvent-free environment significantly alters protein structure, weakening 
hydrophobic while strengthening electrostatic interactions (reviewed in [107]). However, 
analysis of the electron capture dissociation (ECD) fragmentation pattern of a protein in 
an ion trap showed that salt bridges, secondary structure and hydrogen bonds were 
preserved for >4 seconds in vacuum [108]. 
These observations suggest that correctly folded protein species and intact protein 
complexes with a near-native fold can be studied by ESI-MS. Since the 1990s, several 
approaches have been developed, and the ensuing systematic studies found gas 
phase interactions to be partially comparable to solution-phase interactions (reviewed 
in [109]). The two most widely used applications that emerged were the determination 
of gas phase KD values by direct titration, and the comparison of relative complex 
stabilities by collision-induced dissociation (CID) [110]. 
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We have employed both strategies to investigate the substrate requirements for the 
chaperoning effect of the proSP-C BRICHOS domain (Paper VII). Homo-tripeptides 
were used to mimic peptide sequences with specific properties such as hydrophilic, 
hydrophobic, and aromatic segments. The determined ligand preferences correlate well 
with solution phase results (see section 5.1), indicating that this approach can be 
successfully applied to the study of hydrophobic complexes. 
A powerful proof of the possibility to observe even complex protein assemblies intact in 
the gas phase was provided by ion mobility mass spectrometry analysis of 
macromolecular ring-shaped assemblies of the trp RNA-binding protein. The resulting 
data provides compelling evidence for collapse of these rings in the absence of RNA 
molecules, while their presence was found to stabilize the ring structure [111]. 
 
4.1.3 H/D exchange mass spectrometry 
The principle of H/D exchange was demonstrated by Linderstrøm-Lang as early as in 
the 1950s [112]. The speed of exchange of protein backbone amide hydrogens for 
deuterium depends on solvent accessibility and local secondary structure elements and 
can be accelerated or quenched by changes in pH and temperature [113, 114]. 
In 1991, the possibility to measure the exact amount of deuterium incorporation by 
mass spectrometry and its application in the determination of protein folding states was 
demonstrated [115]. The combination of enzymatic digestion of labeled protein, 
separation of the resulting peptides by liquid chromatography, and subsequent mass 
spectrometric quantification of the deuterium incorporation in each fragment can be 
used to identify slow and fast exchanging protein segments and yield information about 
the local protein backbone conformation [116]. 
Most notably, the application of HDX-MS is limited only by the efficiency of the 
enzymatic digestion and the resolution power of the chromatographic peptide 
separation. In recent years, this method was therefore used to investigate the structure 
of proteins that have eluded most conventional NMR and X-ray crystallography 
methods, such as the β-sheet core of Aβ 1-40 [117, 118], prion [119], and insulin [67] 
fibrils. E.g., HDX-MS was successfully utilized to show that in vivo prion aggregates 
have structural features not found in amyloid fibrils generated from recombinant prions, 
which demonstrates the importance of the method [120]. 
We used HDX-MS to obtain information about unstructured segments of proSP-C 
BRICHOS that could not be visualized by X-ray crystallography to locate the ligand 
binding segment in the proSP-C linker region (Paper VIII). We also applied HDX-MS to 
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monitor structural dynamics of the N-terminus of MaSp1 and demonstrated that the pH-
dependent assembly of spider silk is mediated by dimerization and structural tightening 
of the N-terminal domain (Paper X). Both studies illustrate how HDX-MS can 
complement crystallographic protein structure data with information about protein 
regions that could otherwise not be analyzed. 
As described below, we also developed an automatable on-line HDX-MS system for 
dilution-free protein labeling and demonstrate its application by monitoring 
conformational changes in proteins (Paper III). 
 
4.2 H/D EXCHANGE MICROFLUIDICS FOR PROTEIN STRUCTURE ANALYSIS 
(PAPER III) 
 
4.2.1 Problems with conventional H/D exchange strategies 
HDX-MS relies on the dilution of a protein stock solution in a deuterated buffer with a 
final D-content preferably above 80%. This ensures a one-directional exchange of the 
protein backbone hydrogens for deuterium. At fixed time points, the exchange is 
quenched and the incorporation of deuterium into individual protein segments is 
measured by MS. 
This approach has two disadvantages: Firstly, the dilution of a protein stock solution in 
deuterated buffer by a factor of > 5x can only be achieved through the use of 
concentrated protein stock solutions, usually in the high µM or even mM range, which 
requires large amounts of material and can cause unwanted aggregation. Secondly, 
sample preparation involves multiple pipetting steps, which represents an additional 
error source. Hence, a dilution-free, automatable procedure is desirable. 
 
4.2.2 Deuterium delivery via a membrane flow cell 
To overcome these problems, deuterium delivery using a flow cell (HDX cell) with two 
channels separated by an ion-selective membrane was tested (Figure 4). One flow 
channel carries the sample (main channel), the other deuterium oxide (second 
channel). By adjusting the flow rate of the sample, the deuterium incorporation can be 
adjusted, while the flow of the D2O determines the deuterium concentration in both 
channels. The cell can be coupled directly to the ESI inlet of a mass spectrometer or to 
an HPLC system that includes peptic digestion and reverse-phase separation prior to 
MS analysis. 
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Figure 4. Layout of the HDX cell. The upper channel carries D2O and is separated from the sample 
channel by a cation-selective membrane. D+ and H+ ions are freely transferred between the channels, 
allowing for deuterium labeling of protein transported in the sample channel. Reproduced from Paper III. 
 
4.2.3 Method validation 
To determine the amount of labeling afforded by the HDX cell, we measured the on-line 
deuteration of the unstructured [Glu1]-fibrinopeptide B at varying D2O flow rates and 
compared it to the off-line deuteration of the same peptide in buffers containing 
between 10 and 90% D2O. We found that, at a D2O flow rate five times greater than the 
sample flow, a D-content of approximately 80% can be achieved (Figure 5 A), which is 
comparable to that conventionally used for off-line HDX [114]. 
We then investigated whether HDX cell deuteration accurately reflects protein folding 
states. For this purpose, we subjected myoglobin under native or denaturing conditions 
to on-line deuteration. The results indicate a significant increase in backbone labeling 
when denaturing conditions that increase backbone accessibility are employed (Figure 
5 B), which supports the concept. We therefore concluded that global protein folding 
can be monitored by HDX cell deuteration. 
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Figure 5. On-line deuteration using the HDX cell. (A) [Glu1]-fibrinopeptide B is shown as undeuterated 
(top), deuterated on-line in the HDX cell with a D2O flow rate of 10 µL/min and a sample flow rate of 2 
µL/min (middle), and deuterated off-line in 80% D2O, 20% H2O. (B) Deuteration of myoglobin at varying 
flow rates converted to exposure time (see Paper III for details) in H2O (open squares) and in the 
presence of 35% acetonitrile without (black squares) and with heme group attached (open triangles). (C) 
Peptide level HDX profile of MaSp1 NT deuterated in the HDX cell at flow rates between 0.25 and 5 
µL/min. Color coding indicates the degree of backbone labeling in each fragment relative to the maximum 
deuteration observed after off-line labeling in 80% D2O. Adapted from Paper III. 
 
For peptide-level HDX-MS analysis, we equipped the HDX cell setup with a pepsin 
column for on-line proteolytic digestion, as well as a reverse phase column for 
purification of the resulting peptides. On-line deuteration and digestion of the N-terminal 
domain of spider silk MaSp 1 resulted in a deuteration pattern that accurately reflects 
the presence of secondary structure elements as determined by X-ray crystallography 
[50] and conventional HDX-MS (Paper X) (Figure 5 C). It should be noted that protein 
solutions between 10 and 60 µM were employed, which is equivalent to the 
concentrations used during labeling reactions in conventional HDX-MS after dilution.  
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Taken together, our data indicate that (a) the HDX cell can achieve the D+ 
concentrations necessary for effective HDX in the sample channel, and (b) HDX cell-
driven HDX-MS can be used to monitor protein folding at the global and peptide levels 
without the need for concentrated protein stock solutions. 
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5 RESULTS AND DISCUSSION 
 
5.1 CONTROL OF INSULIN AGGREGATION BY PROINSULIN C-PEPTIDE 
 
5.1.1 C-peptide interferes with insulin fibril formation (Paper IV) 
5.1.1.1 C-peptide changes the morphology of insulin amyloid-like fibrils 
Firstly, we investigated the effect of C-peptide on insulin fibrillation. Incubation of insulin 
alone under fibril forming conditions (1 mM insulin at pH 2.5 and 75ºC) in standard 
microcentrifuge tubes resulted in increasing ThT fluorescence after a lag time of 
approximately 3 ½ h and formation of fibrillar structures visible by EM (Figure 6 A, C). 
Co-incubation of equimolar amounts of insulin and C-peptide under these conditions, 
on the other hand, resulted in significantly reduced lag time, with the appearance of 
ThT-postive, rounded aggregates already after 1 h (Figure 6 A and C, top panel). When 
incubation was carried out in Protein LoBindTM tubes, which are designed to prevent 
protein aggregation by lack of nucleation sites, C-peptide was found to significantly 
extend fibrillation lag time (Figure 6 B). In both cases, EM analysis revealed that co-
incubation of insulin and C-peptide resulted in the formation of clumps of short fibrils 
(Figure 6 C, bottom panels). Together, the data suggest that C-peptide interferes with 
the assembly of unfolded insulin into fibrils. 
 
5.1.1.2 C-peptide and insulin interact during fibril formation 
We concluded that these effects must be mediated by a direct molecular interaction 
between C-peptide and insulin. Native ESI-MS spectra during fibrillation lag phase 
show the presence of 1:1 complexes between insulin and C-peptide, indicating that 
both peptides can indeed interact under the buffer conditions employed here. MS 
analysis of solubilized fibrillar material confirmed the presence of both insulin and C-
peptide in the aggregates. Additionally, we performed short-time deuterium labeling of 
insulin + C-peptide fibrils. Labeled fibrils were dissolved in formic acid and subjected to 
MS analysis. We observed two separate insulin populations: one with labeling behavior 
similar to that of fibrillated insulin, the other with additional backbone protection. This 
suggests the presence of two molecular conformations, which is indicative for 
additional structural arrangement of the insulin fibrils, or continued interactions of C-
peptide with the insulin fibrils. 
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Figure 6. C-peptide interferes with insulin fibril formation. (A) ThT fluorescence time course shows 
acceleration of insulin fibrillation by C-peptide in regular microcentrifuge tubes. (B) Co-incubation of C-
peptide and insulin in Protein LoBindTM microcentrifuge tubes delays insulin fibrillation. Error bars indicate 
standard deviation from four separate incubations. (C) Aggregate morphology in ThT fluorescence 
microscopy (top and middle row) and EM (bottom row). Co-incubation of insulin and C-peptide caused 
the appearance of small, round, ThT-positive aggregates after 1 h. Electron microscopy shows clumps of 
short, thick fibrils from co-incubation of insulin and C-peptide. Scale bars indicate 200 µM in fluorescence 
microscopy images and 200 nm in EM micrographs. Reproduced from Paper IV. 
 
5.1.1.3 C-peptide as a regulator of amyloid fibril formation 
Two previous studies by others have reported no effect of C-peptide on insulin 
fibrillation at pH 2.0 [121] and 7.3 [122]. However, both studies were conducted using 
low rather than high insulin concentrations (60 and 2.5 µM, respectively) in salt-
containing buffers (150 and 100 mM NaCl, respectively). However, the salt 
concentration found in secretory exceeds that of insulin by a factor of only 5 to 10 [123], 
and insulin fibrils observed at the injection sites in diabetic patients are likely the result 
of high local insulin concentrations. Standard insulin injection solutions contain between 
0.7 and 1 mM insulin and no NaCl. Since salt and insulin concentration have been 
described as important factors in insulin fibrillation, it is likely that use of such near-
millimolar concentrations in the absence of salt cause insulin aggregation [73]. Thus, 
C-peptide can stabilize insulin under these conditions, opening the possibility to control 
insulin aggregation by an endogenous peptide. 
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Interestingly, the effects of C-peptide on islet amyloid polypeptide (IAPP) fibrillation are 
similar to those reported here. The presence of C-peptide caused significantly 
accelerated IAPP aggregation, leading to reduced Congo Red staining intensity and 
incorporation of C-peptide into fibrils with altered morphology [124, 125]. The proposed 
mechanism that the negatively charged C-peptide forms a stabilizing complex with the 
unfolded, positively charged IAPP monomer in solution, but can accelerate fibril 
formation if nucleation points are present, is compatible with our findings on the effect 
of C-peptide on insulin fibrillation. This raises the possibility of C-peptide being a 
general regulator of β-cell granule peptide amyloid formation (see section 5.1.3). 
 
5.1.2 pH-dependent regulation of insulin solubility by C-peptide (Paper V) 
5.1.2.1 C-peptide co-precipitates with insulin at pH 5 
Having established that C-peptide affects the state of insulin under fibril-forming 
conditions, we asked whether C-peptide could exert a similar effect on insulin at pH 
values between 5 and 6, i.e. around the isoelectric point of insulin. Insulin processing in 
the secretory granules occurs at this mildly acidic pH range [126]. Its reduced solubility 
under these conditions is thought to drive the processed insulin into complex formation 
with the abundantly present zinc ions and subsequent crystallization [127]. The crystals 
are released into the bloodstream as long-acting insulin together with a fluid, acidic 
phase containing C-peptide and soluble insulin [128], suggesting that C-peptide 
participates in intragranular sorting [129]. 
Previously, we have employed native ESI-MS to monitor the effect of C-peptide on 
insulin oligomers observed at pH 5 that represent pre-fibrillar aggregates [63]. C-
peptide removed insulin multimers from the ESI-MS spectra, which was interpreted as 
a desaggregating effect on insulin [61, 130]. We employed spectrophotometry and 
microscopy to monitor the effect of C-peptide on insulin oligomers at pH 5. Surprisingly, 
we observed a direct increase in the optical density at 500 nm (OD500) of concentrated 
insulin solutions after the addition of equimolar amounts of C-peptide, indicating that 
the presence of C-peptide causes immediate precipitation. Isolation by centrifugation 
and subsequent ESI-MS analysis confirmed that the precipitate contains both C-
peptide and insulin, while only C-peptide was found in the supernatant. The sub-
stoichiometric incorporation of C-peptide was investigated by spectrophotometric 
analysis of solutions containing insulin and C-peptide at ratios between 1:1 and 1:32. 
Only solutions containing an insulin/C-peptide ratio of 1 or 2 were found to precipitate, 
which shows a strict stoichiometry of one C-peptide per two insulin moieties. 
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5.1.2.2 Co-precipitation is dependent on conserved C-peptide charges 
To investigate whether co-precipitation provides an explanation to the observed 
removal of insulin oligomers from ESI-MS spectra, we repeated the ESI-MS studies 
with C-peptide analogues in which the conserved glutamate residues at positions 11 
(E11A) or 27 (E27A) or 3, 11 and 27 (E3,11,27A) were replaced by alanines. None of 
the three peptides caused an increase in OD500 when mixed with insulin at equimolar 
ratios. Similarly, the presence of 100 mM NaCl inhibited co-precipitation, while increase 
of the pH to > 7.5 immediately dissolved the precipitate, showing that its formation 
depends on charged residues. 
ESI-MS spectra of insulin in the presence of the E11A and E27A C-peptide variants 
showed only a minor reduction of insulin oligomers, while no reduction was observed 
the case of the E3,11,27A variant. All three variants formed heteromers with insulin 
oligomers at sub-stoichiometric amounts of C-peptide. CID-analysis revealed that 1:1 
complexes between insulin and wt C-peptide have the same gas phase stability as 
those formed between insulin and the E11A or E27A variants, while insulin complexes 
with the E3,11,27A variant had a lower gas phase stability. 
 
5.1.2.3 C-peptide-insulin interactions via mutual charge neutralization 
Insulin has a net charge of +2 at the mildly acidic pH during secretion that was 
employed in this study. At the same pH, C-peptide has a net charge of -4 due to its four 
glutamate residues, three of which are the only largely conserved residues in the C-
peptide sequence. A complex of two insulin molecules and one C-peptide would have 
a net charge of 0, thus lowering its solubility and causing precipitation. This is 
supported by evidence from gas phase interaction studies: All three C-peptide variants 
do not co-precipitate with insulin and cannot remove insulin oligomers from the ESI-MS 
spectra, but form instead non-covalent complexes. This indicates that the presence of 
two or three glutamate residues is sufficient for the formation of 1:1, but not 1:2 
complexes with insulin. Removal of three glutamate residues, however, significantly 
decreases the stability of the 1:1 complex. This is compatible with wt C-peptide binding 
two insulin molecules together via its negative charges in a “handcuff”-like manner 
(Figure 7). Removal of one charge on C-peptide leaves one of the two interactions 
intact, while the removal of three charges weakens the remaining interaction. In all 
cases, the complex net charge is <0 and the complex retains its solubility. 
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Figure 7. Proposed model for pH-dependent regulation of insulin solubility by C-peptide. At pH 5, C-
peptide has a net charge of -4, while insulin has a net charge of +2. We propose a “handcuff”-like 
mechanism by which insulin forms a 2:1 complex with C-peptide that has a net charge of 0 and 
precipitates. 
 
5.1.2.4 Implications for the prevention of insulin fibrillation in vivo 
Several studies have raised the question why insulin does not form amyloid at the 
extreme concentration found in the secretory granules, which can exceed 20 mM [123]. 
It has previously been thought that zinc crystal formation catches poorly soluble 
processed insulin and thus prevents insulin fibrillation. However, it has been shown that 
zinc is not essential for production and release of biologically active insulin from 
pancreatic β-cell granules [131]. Additionally, the insulin released from the C-peptide-
rich acidic fluid phase is biologically active, and not all granules contain zinc-insulin 
crystals [128]. 
To date, only one charge-altering C-peptide mutation has been investigated for its 
potential to alter insulin processing and release, and no negative effects were detected 
[132]. We propose a balance between zinc-mediated crystal assembly and C-peptide 
mediated, pH-dependent precipitation. The lowered pH following proinsulin cleavage 
[126] could cause protonation of insulin B-chain histidine residue 10, which is known to 
prevent zinc crystal formation [133]. Thus, minor pH-changes could steer insulin into 
crystallization or precipitation to balance the amount of long-acting and rapid-acting 
release forms.  
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5.1.3 Peptide interactions and protein aggregation in diabetes (Paper VI) 
 
5.1.3.1 C-peptide as an aggregation inhibitor in vivo? 
As described above, in vitro studies show that C-peptide interacts with both insulin and 
IAPP to prevent uncontrolled aggregation, and either type of interaction is charge-
based and therefore pH-sensitive. In both cases, the effective pH range is close to that 
found in the secretory granules, where the peptides co-localize in the halo region. 
In diabetes types 1 and 2, the synthesis and processing of granular peptides is 
impaired. Since insulin has an inhibitory effect on IAPP aggregation [134], it has 
previously been suggested that diabetes-associated disturbances in peptide synthesis 
and processing promote IAPP aggregation and contribute to β-cell dysfunction [135]. 
However, reduction in insulin processing too small to abolish the inhibitory effect on 
IAPP aggregation [136]. Similarly, diabetes-related changes in insulin levels do not 
affect the insulin:C-peptide ratio, and no insulin amyloid deposits have been found in 
the secretory granules. Therefore, does the finding that C-peptide can control IAPP and 
insulin aggregation in vitro have any relevance in vivo? 
 
5.1.3.2 Peptide ratio imbalances may contribute to diabetes-associated protein aggregation 
Even though the changes in ratios of insulin, C-peptide and IAPP as well as their 
respective proforms at different diabetic stages are individually too small to affect 
peptide aggregation, they do represent a significant deviation from normophysiology 
that is exacerbated as the disease progresses. In this work, we present evidence that 
C-peptide interacts with insulin and IAPP through the same mechanism, and therefore 
propose that their interactions in the secretory granules are more complex than 
previously thought. 
In Paper V, we have proposed that a balance between charge-based co-precipitation 
with C-peptide and zinc-mediated crystallization contributes to intragranular insulin 
sorting. It has been suggested that similar charge-based interactions with C-peptide 
localize IAPP to the halo region [134]. Therefore, if peptide relative or absolute 
amounts are disturbed, such a sorting mechanism might function less efficiently or 
become non-functional. In this scenario, lowered amounts of C-peptide and insulin but 
continued high zinc content could drive insulin exclusively into crystallization. 
Alternatively, lowered amounts of C-peptide could be insufficient in recruiting and 
binding IAPP to the halo region. In both cases, IAPP would be sequestered from 
aggregation inhibition. 
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The sorting mechanism via insulin crystallization and C-peptide precipitation also offers 
an explanation to the fact that neither the exclusion of zinc from the secretory granule 
[131] nor charge-altering C-peptide mutations [132] lead to the formation of insulin 
aggregates. When both stabilizing components are lacking, as it is the case during 
administration of recombinant insulin in insulin-dependent diabetes of both types, 
insulin aggregates can form. In this sense, localized insulin amyloidosis can be 
considered an extreme case of diabetes-associated peptide imbalance. 
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5.2 UNRAVELLING THE ANTI-AMYLOID ACTIVITY OF BRICHOS DOMAINS 
 
5.2.1 Binding specificity of proSP-C BRICHOS (Paper VII) 
5.2.1.1 Monitoring BRICHOS-peptide interactions by ESI-MS 
Based on the previously established anti-amyloid activity of CTC, we set out to 
determine the molecular determinants for substrate recognition by the BRICHOS 
domain using native ESI-MS to determine gas phase binding constants through direct 
titration and relative gas phase binding energies through CID. Target peptide 
sequences were modeled by homo-tripeptides composed of small (AAA, GGG), 
hydrophobic (LLL, VVV), charged (KKK) and aromatic (FFF, YYY) amino acids, all of 
which were amidated and acetylated to mimic longer protein segments. Additionally, 
we included amyloidogenic peptides (KFFE [13], Aβ1-40) and a non-amyloidogenic β-
hairpin peptide (KFFEYNGKKFFE, in the following termed “YNGK” [137]). These 
peptides were mixed at increasing concentrations with the purified proSP-C BRICHOS 
domain. Free protein [P] and the non-covalent complexes [66] were quantified directly 
from the spectra. The gas phase KD was then derived by plotting the [66]/[P] ratio 
against the total ligand concentration [66]. 
We found that VVV had the lowest KD of all tested peptides (summarized in Table 1), 
which fits well with the valine-rich natural target sequence of SP-C. The KD observed 
for the hydrophobic aromatic peptide FFF was similarly low, while the hydrophobic 
peptide LLL had a much higher gas phase KD. The highest gas phase KD was 
observed for the YYY peptide, indicating that the introduction of hydroxyl groups 
significantly lowers binding. Interestingly, we observed a low gas phase KD for the 
YNGK peptide, indicating that BRICHOS can also interact with β-hairpin peptides. 
By measurement of the amount of intact protein-peptide complexes using CID with 
increasing collision voltages, we were able to derive relative gas phase stabilities for 
binding of each model peptide to the BRICHOS domain. Their order (from low to high 
stability) was determined to be GGG < VVV ≈ LLL ≈ KFFE ≈YNGK < FFF < YYY. Due 
to its greater length, Aβ1-40 may interact with the BRICHOS domain at multiple sites and 
is therefore not suitable for direct comparison with shorter model peptides. We 
concluded that the complexes with the highest gas phase stability are formed by 
interaction with aromatic residues. Since it has been shown that four conserved 
tyrosine residues in the BRICHOS domain can be involved in ligand binding [80], it is 
possible that this tyrosine-rich environment can be responsible for the increased gas 
phase stability. 
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Table 1. Apparent dissociation constants (KD) and maximum binding (Bmax) for peptide ligands to the 
proSP-C Brichos domain. See Paper VII for details. 
Peptide Apparent KD (µM) Bmax R2 a 
AAA, KKK - b - b - b  
KFFE - c - c 0.710 
Aβ40 - d - d 0.988 
GGG - e - e 0.998 
YYY 45 0.71 0.980 
LLL 17 0.18 0.967 
YNGK 1.7 0.11 0.996 
FFF 1.4 0.27 0.928 
VVV 1.2 0.07 0.979 
a
 Linear correlation (0 = no correlation, 1 = perfect correlation) 
b
 No quantifiable interaction observed. 
c
 No interpretable titration data. 
d
 KD outside of practical titration range. 
e
 Unspecific interactions. 
 
5.2.1.2 BRICHOS gas phase and solution phase ligand preferences are comparable 
To validate whether the derived gas phase ligand preferences are compatible with in-
solution data, we compared the apparent KDs with results obtained from a membrane 
binding assay, where segments composed of a single amino acid were spotted on a 
cellulose membrane, incubated with S-tagged recombinant CTC, and subjected to 
immunodetection with an S-tag-reactive antibody. Subsequent quantification of the 
amount of CTC bound to each spot confirmed that hydrophobic and aromatic residues 
are the preferred binding partners of CTC [86]. Therefore, the gas phase results are 
comparable to those obtained under solution conditions and suggest that native ESI-
MS can be utilized in the investigation of hydrophobic interactions. 
 
5.2.2 The molecular action of the proSP-C BRICHOS domain (Paper VIII) 
5.2.2.1 The high-resolution proSP-C BRICHOS structure 
To map the interaction of CTC with amyloidogenic peptides at the molecular level, 
determination of its high-resolution crystal structure was carried out in collaboration 
with the group of Prof- Stefan Knight (SLU, Uppsala). After several crystallization 
attempts proved unsuccessful, it was found that treatment of full-length CTC with 
trypsin yielded material suitable for crystallization. MS analysis revealed that the 
crystallized protein lacked the N-terminal linker region and a shorter segment close to 
the C-terminus.  
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The crystallized protein encompassed thus residues 82-160 and 168-197 linked by two 
disulfide bridges and includes most of the conserved BRICHOS domain. The crystal 
structure determined at 2.1 Å shows a trimer. Each subunit contains a central five-
stranded β-sheet enclosed by an α-helix on each side. One side of the beta sheet 
plane (face A) is lined with strictly conserved hydrophobic residues including the 
tyrosines previously suggested to be involved in peptide binding. However, access to 
this surface is in the crystal structure blocked by the α-helix composed of residues 134-
145 (helix 1). Mapping of the conserved residues in the SFTPC sequence showed that 
the strictly conserved aspartic acid in position 105 is in contact with the C-terminal α-
helix 182-190 (helix 2) and could mediate the position of both helices via non-covalent 
interactions. Molecular dynamics simulations carried out by Prof. Johan Åqvist and 
colleagues (Uppsala University) of D105Y and D105G CTC mutants resulted in partial 
unwinding of helix 2, which in turn moves helix 1 away from face A by 5-7 Å, thus 
making face A solvent accessible. It was therefore concluded that interactions via 
aspartic acid 105 could regulate the contact between face A and a hydrophobic ligand. 
This hypothesis is supported by the observation that mutations of D105 are associated 
with ILD in humans. 
We then mapped the structure of the segments that were proteolytically removed in 
order to facilitate crystallization by performing HDX-MS of full-length CTC. Interestingly, 
no individual peptic peptides from the regions encompassing residues 110-161 and 
180-197, which corresponds to the crystallized segment of CTC were observed, 
indicating that this region is highly protease-resistant even at pH 2. Of the segments 
that could be digested and subsequently analyzed by HDX-MS, the linker region 
(residues 67-84) and the short peptide spanning residues 161-179 acquired full 
deuterium labeling within 60 seconds. This indicates that the non-crystallizable 
segments are in fact unstructured in solution, which explains their inhibitory effect on 
CTC crystallization.  
 
5.2.2.2 CTC interacts with peptide ligands via its flexible linker region 
To determine whether the chaperoning effect of CTC on polyvaline target peptides can 
be monitored, HDX-MS of CTC was conducted in the presence of peptides containing 
5 or 7 valines (V5 and V7) or alanines (A7) flanked by two lysine residues at each end. 
Comparison of the deuteration pattern of the polyvaline peptides in the absence and 
the presence of CTC shows that CTC induces significant protection from exchange in a 
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subpopulation of ligand peptides (Figure 8). This effect is more pronounced in the 
longer V7 peptide, while no additional protection is observed for the A7 peptide. 
To determine whether a distinct segment within CTC mediates this effect, we 
performed the same experiment with a construct encompassing only the BRICHOS 
domain, as well as a synthetic peptide corresponding to the linker segment only 
(residues 68-84). In case of the BRICHOS domain, only a minor increase in protection 
of the V7 peptide could be observed, while the linker alone had no effect. 
 
 
Figure 8. CTC induces increased protection from deuterium exchange in long polyvaline segments. A 
subpopulation of the V7 (left column) and to a lesser extent V5 (middle column) peptide show lower 
deuterium uptake in the presence of CTC. This effect is greatly reduced when only the BRICHOS domain 
is present. Labeling of the A7 peptide (right column) is not influenced by CTC. 
 
Monitoring the deuterium exchange pattern of the linker region (as the BRICHOS 
domain was inaccessible to peptic digestion) in the presence and the absence of the V7 
peptide showed that the N-terminal peptide encompassing residues 68-71 (VLEM) 
incorporates significantly less deuterium when a polyvaline segment is present (Figure 
9). This indicates the induction of a secondary structure element in this region. We 
therefore propose a model in which the polyvaline segment is bound to face A of the 
BRICHOS domain in extended conformation while the linker region forms a 
complementary β-strand (Figure 9). 
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Figure 9. A schematic model of CTC action derived from HDX-MS data. A polyvaline peptide interacts 
with face A of the BRICHOS domain (grey arrow). The unstructured linker segment (red) forms a 
complementary β-strand (red arrow), which traps the amyloidogenic peptide in extended conformation 
and increases protection from deuterium labeling in both segments. Reproduced from Paper VIII. 
 
5.2.2.3 CTC mutations cause amyloid formation in vivo 
The importance of the linker region for the biological function of CTC is illustrated by 
the observation that the most prevalent mutation, in which an isoleucine in position 73 
is replaced with a threonine, is located only two residues away on the C-terminal side 
of the VLEM fragment that is involved in peptide ligand binding (Figure 9), suggesting 
that the introduction of a polar amino acid in this region can interfere with the 
interaction of the linker with the SP-C transmembrane segment.  
To investigate whether CTC malfunction can give rise to amyloid in vivo, the group of 
Prof. Per Westermark (Uppsala University) performed histological screening of lung 
sections obtained from seven patients with mutations in the CTC region. In all but one 
case, microdeposits composed of mature SP-C were observed that showed green 
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birefringence upon Congo Red staining when viewed under polarized light, as well as 
immunoreactivity of serum amyloid P component, which both are hallmarks of amyloid 
deposits. Therefore we concluded that CTC exerts its anti-amyloid function in vitro and 
in vivo via both linker and BRICHOS domain, and the ILD cases reported here an 
instance of an amyloid disease caused by specific chaperone dysfunction. 
 
5.2.3 Function of the Bri2 BRICHOS domain (Paper IX) 
5.2.3.1 Bri2 has anti-amyloid activity in vitro 
Parallel to our studies on the BRICHOS domain structure, it was investigated whether 
the anti-amyloid activity observed for the proSP-C BRICHOS domain can also be 
exerted by the BRICHOS domain of Bri2 (ITM2B). This was carried out using a cloned 
and purified a construct encompassing residues 90-236 of the Bri2 protein, which 
includes the BRICHOS domain but not the 23-residue C-terminal peptide. The 
presence of the single intramolecular disulfide bond was confirmed by chemical 
reduction and MS. 
Next, we asked if the Bri2 BRICHOS domain is able to prevent Aβ1-40 aggregation in 
vitro. While Aβ1-40 alone was found to aggregate within 7h, incubation of Bri2-BRICHOS 
with Aβ1-40 at ratios between 1:1 and 1:10 prevented amyloid fibril formation within the 
24 h period studied, as judged by ThT fluorescence. EM of solutions containing a 1:1 
solution of Aβ1-40 and Bri2 BRICHOS showed no amyloid fibrils even after 5 days of 
incubation at room temperature. 
 
5.2.3.2 The Bri2 BRICHOS domain interacts with aromatic peptides 
In an approach based on that presented in Paper VII, we employed ESI-MS to study 
interactions between Bri2-BRICHOS and its potential target peptides, the 23-residue 
Bri23 peptide of unkown function, and Aβ1-40. We observed the non-covalent 
complexes between Bri2 BRICHOS and either peptide. However, only a minor fraction 
of Bri2 BRICHOS was found to interact with Aβ1-40, while the presence of equimolar 
amounts of Bri23 was able to nearly completely saturate Bri2 BRICHOS. In competition 
between Aβ1-40 and Bri23, Aβ1-40 was unable to displace Bri23 from the Bri2 BRICHOS 
domain, indicating that the latter binds Bri23 with high affinity. 
We then specified the preferred peptide ligand features by screening the homo-
tripeptide library employed for proSP-C BRICHOS. Unfortunately, the Bri2 BRICHOS 
construct proved to be less suitable for native ESI-MS, which prevented the 
determination of gas phase KDs. However, we were able to perform qualitative binding 
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studies and observed that only tyrosine-containing ligands were able to interact with 
Bri2 BRICHOS in the gas phase. We therefore conclude that proSP-C and Bri2 
BRICHOS domains have only partially overlapping ligand preferences, indicating that 
they possibly exert their anti-amyloid activity by targeting different regions in their 
ligands: While both domains are capable of interacting with peptides containing 
aromatic residues, which are enriched in amyloidogenic peptides [11], proSP-C 
BRICHOS is additionally adapted to polyvaline segments to suit its biological function. 
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5.3 CONTROL OF PH-DEPENDENT SPIDER SILK ASSEMBLY 
 
5.3.1 pH-dependent action of the MaSp1 NT domain (Paper X) 
5.3.1.1 MaSp1 NT dimerizes in a pH-dependent manner 
To gain insights into the assembly of the MaSp1 NT domain, we recorded native ESI-
MS spectra of wt and mutant NT in which conserved aspartate and glutamate residues 
(D40, E79, E84, and a D40E84 double mutant) are substituted for their uncharged 
counterparts asparagine and glutamine. Interestingly, we observed that lowering the 
pH from 7.0 to 6.0 resulted in a shift from mostly monomeric to dimeric wt NT protein 
(Figure 10), with a sharp transition between pH 6.4 and 6.3, the same pH step at which 
the NT domain was found to accelerate assembly of recombinant MaSp1 constructs. 
The D40, E84 and D40E84 mutants showed no increase in dimer formation at this pH 
step, while mutation of the non-conserved E79 did not affect dimerization. We therefore 
conclude that charge-dependent dimer formation could trigger pH-dependent 
assembly. 
 
5.3.1.2 In-solution dimerization is accompanied by global fold tightening 
To investigate whether the observed dimerization occurs in solution, we performed 
HDX-MS analysis of the NT domain at pH 6.0 and 7.0 in the presence and absence of 
300 mM NaCl, and of the non-dimerizing D40E84 double mutant. Since deuterium 
exchange is accelerated by one order of magnitude when the pH is increased one unit 
[114], labeling times at pH 6.0 were extended by a factor of 10 to facilitate direct 
comparison of the deuterium incorporation under both conditions. 
Comparison of the HDX-MS profiles at both pH values revealed a significant increase 
in backbone protection for helix 2 and 3, which are located at the dimer interface as 
determined from the crystal structure (Figure 10). This suggests that the dimerization 
observed by native ESI-MS occurs in solution. Interestingly, we also observed reduced 
deuterium uptake in peptides from the hydrophobic core of the 5-helix bundle. We 
interpreted this as global tightening of the NT domain, which could be a prerequisite or 
a result of its dimerization. 
It should be noted that both conclusions -dimerization and fold tightening- were 
subsequently confirmed by an NMR study [138]. 
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Figure 10. Monitoring structural dynamics in the MaSp1 N-terminal domain by mass spectrometry. The 
helical MaSp1 NT domain dimerizes when the pH is lowered from 7 (left) to 6 (right). The dimerization 
can be followed by an increased protection from H/D exchange in peptides located at the dimer interface 
as well as an increase in non-covalent dimers in ESI-MS spectra recorded at low pH. Reproduced from 
Paper II. 
 
5.3.1.3 Structural changes are dependent on salt and conserved residues 
The HDX-MS profiles of the D40E84 double mutant and wt NT in the presence of 300 
mM NaCl showed two opposing effects. While NaCl caused globally reduced 
deuterium incorporation, the double mutant exhibited overall increased labeling. In both 
cases, however, no pH-dependent differences in deuteration could be observed, which 
shows that either change affects the ability of the NT domain to dimerize in a pH-
dependent manner. The inhibitory effect could be mediated by shielding charged 
residues and forcing the protein into a more condensed structure to hide the 
hydrophobic core at high salt concentrations, or by global destabilization in the case of 
the D40E84 double mutant. Based on these data, we were able to formulate a role for 
the NT domain in spidroin assembly: The decrease in pH and salt during spidroin dope 
extrusion causes MaSp1 dimerization of the N-terminal domains. While two spidroin 
molecules are aligned by the parallel, covalent C-terminal domains, each NT domain 
links one half of this dimer to another dimer via its antiparallel dimerization ability. The 
arising crosslink pattern can in theory give rise to an infinite chain of MaSp1 molecules. 
Shear force and altered salt concentration triggers conversion of the C-terminal domain 
to its fiber-promoting form which initiates fiber formation. 
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5.3.2 The structure of monomeric MaSp1 NT (Paper XI) 
 
5.3.2.1 The A72R NT mutant is monomeric 
In order to pinpoint the structural mechanisms behind pH-dependent NT dimer 
formation, the structure of its monomeric form had to be determined. Since X-ray 
crystals structures only show the dimeric form of NT, we designed a non-dimerizing 
mutant, in which alanine 72, located at the center of helix 3 and extended into the 
dimer interface, was replaced by arginine (A72R). The positive charge and bulky side-
chain of arginine should prevent dimer formation and thus facilitate study of the 
monomer at a wide pH range. 
This was confirmed by tryptophan fluorescence spectroscopy and HDX-MS studies 
which show that neither the pH-dependent change in W10 fluorescence nor additional 
protection of helix 2 and 3 from deuteration occur in A72R at low pH. Interestingly, 
A72R also fails to exhibit the observed tightening of the subunit core at pH 6, 
suggesting that it is a result of dimer formation rather than a prerequisite. 
 
5.3.2.2 Monomeric and dimeric NT show distinct structural differences 
Structure determination of A72R by both NMR and X-ray crystallography proved 
successful, yielding NT structures at low and high pH. An additional NMR study of wt 
NT at pH 7.2 in the presence of 300 mM NaCl further confirmed that the A72R 
replacement did not affect the monomer structure. Therefore, a direct comparison of all 
structures is possible. 
Under all conditions, NT retains the overall architecture of a 5-helix bundle observed in 
the dimer structure. However, in monomeric form, helix 1, 4 and 5 are rotated relative 
to helix 2 and 3, which requires the relocation of W10 from a hydrophobic crevice into a 
solvent-exposed conformation, thus explaining the observed differences in tryptophan 
fluorescence. However, no differences could be observed between the structures of 
A72R at pH 6 and 7, which suggests that the rotation of the helices only occurs in 
connection with dimerization, not as an isolated movement in connection to the pH 
change.  
 
5.3.2.3 A possible mechanism for dimer formation 
Since dimer formation must be regulated by conserved acidic residues, we compared 
their localization in monomeric and dimeric NT. In the NT dimer, the two highly 
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conserved residues D40 at the beginning of helix 2 and E84 at the end of helix 3 can 
form an intramolecular handshake interaction [50]. This interaction is lost in monomeric 
NT, where the two carboxylates are more than 10 Å apart, and this is accompanied by 
unwinding of the last half-turn of helix 3. This could be due to the lack of positive 
charges R60 and K65 on the opposing subunit, which are predicted to form salt bridges 
with the negatively charged cluster composed of residues D39, D40 and E84. ESI-MS 
and HDX-MS show that D40 and E84 are crucial for dimer formation, but are predicted 
to have a pKa below pH 6 and are therefore unlikely to act as a pH sensor between pH 
6 and 7. 
To compare the structural changes upon dimerization, we constructed a hypothetical 
dimer composed of monomers by superimposing helices 2 and 3 in monomeric NT with 
the corresponding helices in each subunit in the wt NT dimer. The hypothetical dimer 
shows that the rotation of helix 5 causes steric clashes with helix 5 on the other subunit 
(Figure 11). The conserved glutamic acid residues E84 and E79 as well as the non-
conserved E119 are protected from the solvent in the wt NT dimer, but become more 
solvent-exposed in the hypothetical dimer. 
Interestingly, this is in partial agreement with molecular dynamics simulations of the wt 
NT dimer which predict that deprotonation of E79 and the non-conserved E119 above 
pH 6 allow water molecules to enter the dimer interface, causing outward rotation of 
helix 5, and thus destabilizing the dimer. Our data suggest that above pH 6, the 
repulsive charge from E79, which is predicted to have a pKa between pH 6 and 7, 
prevents helix 5 from moving into the position that it occupies in the wt dimer. This is 
supported by ESI-MS experiments that show that the non-charged E79Q mutant is 
able to dimerize at both pH 7 and 6. Similarly, protonation of E119 could also reduce 
repulsion in this region. However, its low degree of conservation as well as the 
observation that replacement of E79 alone is sufficient to allow dimerization suggests 
that this residue is not crucial for pH-dependent dimerization. 
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Figure 11. Dimerization of NT requires structural rearrangement of the monomer subunit and burial of 
glutamic acid residues. Comparison of the crystallographically determined wt NT dimer (left) and a 
hypothetical dimer constructed from wt monomeric NT subunits (right) as side and top view. Helix 1-4 in 
each dimer are shown as surface representation and helix 5 as cartoon. The side chains of E79, E84 and 
E119 are shown as a sphere models, clashing residues on helix 5 as stick representation. The 
hypothetical dimer was constructed by superimposing helices 2 and 3 in monomeric NT with the 
corresponding helices in each subunit in the wt NT dimer. 
 
Together with the experimental evidence from the monomeric NT structure, 
conclusions about the pH-dependent dimerization mechanism can be formulated. 
Between pH 4 and 8, salt bridges involving the D39, D40, and E84 cluster together with 
R60, and K65 allow the association of two NT monomers via helix 2 and 3. However, 
the negative charge of E79 at pH 7 prevents helix 5 from moving into a clash-free 
position. At pH 6, its protonation allows the block of helix 1, 4, and 5 to rotate towards 
the interface and form interactions with its counterpart on the other subunit, excluding 
water from the interface and stabilizing the dimer (Figure 11). 
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5.3.3 The MaSp-1 N-terminal domain as a solubility tag (Paper XII) 
5.3.3.1 MaSp1 NT as solubility-enhancing tag for protein purification 
During expression and purification of recombinant NT domain variants, the wt NT 
domain could be easily expressed with high yields and stored at concentrations in the 
mM range without loss of folded, soluble protein. It appears likely that the NT domain, 
besides its dimerization ability, could function as a solubility tag that helps to stabilize 
MaSp proteins during storage in the ampullate gland. 
To test this hypothesis, constructs were generated that encompassed one or two NT 
domains and SP-C33Leu, an SP-C variant composed of poly-leucine instead of poly-
valine, which retains regular SP-C function while being less aggregation-prone . To be 
able to compare the efficiency of using the NT domain as solubility-enhancing tag, 
constructs in which SP-C33Leu was fused to the commonly used solubility tag 
thioredoxin (Trx) were also generated. All constructs included an N-terminal His6-tag for 
affinity purification. SP-C33Leu could be released from the fusion protein by CNBr 
cleavage and recovery in a two-phase system of chloroform/methanol/water. 
 
5.3.3.2 Fusion with MaSp1 NT increases protein expression and yield 
While the SP-C33Leu construct tagged with Trx was expressed only at low levels, all 
the constructs tagged with one or two NT domains were expressed with high yield. The 
construct encompassing two NT domains was recovered from the soluble fraction of 
the bacterial lysate, while the fusion protein with a single NT domain could be purified 
from the membrane fraction with the addition of the detergent. This indicates that the 
hydrophobic SP-C33Leu is inserted into the bacterial membranes when fused to a 
single NT domain, and thus anchors the entire construct to the lipid fraction. The use of 
a single Trx tag alone, on the other hand, does not provide enough solubility.  
To test whether intact SP-C33Leu can be released from the purified fusion protein, we 
subjected the CNBr-cleaved SP-C33Leu to ESI-MS analysis and sequencing by CID. 
Spectra of SP-C33Leu in 100% ethanol show pure SP-C33Leu with four or three 
charges, as well as a dimeric form with seven charges (Figure 12 A). CID of the 
[M+3H]3+ peak confirmed that full-length SP-C33Leu had been recovered (Figure 12 B). 
Together, the data show that the NT domain can be used as potent solubility tag in the 
purification of hydrophobic peptides that are difficult to express and purify using 
conventional strategies. Furthermore, the data support the possibility that this feature of 
the NT domain could be part of its function in vivo by increasing the solubility of MaSp 1 
to facilitate storage in the ampullate gland. 
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Figure 12. Characterization of SP-C33Leu recovered from NT domain fusion proteins. (A) ESI-MS shows 
the presence of CNBr-cleaved SP-C33Leu. (B) CID of the [M+3H]3+ peak confirms the presence of full-
length SP-C33Leu. Reproduced from Paper XII. 
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6 CONCLUSIONS AND OUTLOOK (PAPER XIII) 
 
In this thesis, we have presented insights into the control of amyloid formation by 
autoregulatory elements in amyloidogenic (pro)proteins at the molecular level. This 
thesis proposes that C-peptide modulates insulin solubility via direct molecular 
interactions that can interfere with amyloid fibril formation, establishes that trapping an 
amyloidogenic segment in a β-hairpin conformation by the BRICHOS chaperone 
domain prevents the aggregation of SP-C, and demonstrates that dimerization of a 
solubility-conferring domain mediates pH-dependent assembly of spider silk. 
At the time of writing, three additional systems have been described in which amyloid 
formation is controlled by distinct autoregulatory elements. The N-terminal side of the 
yeast HET-s prion co-aggregates during amyloid formation by HET-S protein, which 
causes refolding of its C-terminal domain. This terminates fibril extension and thus 
controls non-genetic heredity in yeast [139]. The fungal surface modifier protein EAS 
can contain or release its amyloidogenic segment based on exposure to an air:water 
interface [140]. The human melanin synthesis scaffold protein Pmel17 contains 
glutamic acid residues that allow self-association only at the acidic pH found in 
melanosomes [141]. 
Additionally, two functional amyloid systems are suggested to employ autoregulatory 
strategies: The Drosophila CPEB homolog Orb2a contains a short 8-residue segment 
that changes the amyloid formation propensity of its glutamine-rich prion domain and 
thus initiates the formation of amyloid-like oligomers in Drosophila mushroom body 
neurons that facilitate long-term memory [142], and storage of peptide hormones has 
been suggested to occur in amyloid form, with currently undetermined aggregation and 
resolubilization steps [48]. 
The involvement of amyloid in such highly complex systems suggests a special role for 
its regulation in biology and leaves much to be investigated. Even within the limited 
scope of this thesis, several questions remain unanswered, as summarized below. 
 
1. We propose a mechanism by which intravesicular pH controls a balance of C-
peptide- and zinc-mediated insulin phase transitions. This implies that a possible 
reason this mechanism has gone unnoticed is the requirement for a double 
mutation to generate a loss-of-function phenotype. For the biogenesis of C-
peptide-related neonatal diabetes (i.e. impaired secretion of functional insulin 
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due to genetic causes), the ZnT8 transporter required for Zinc homeostasis in 
the secretory granules would have to be impaired [131] and one or more 
conserved glutamate residues in C-peptide must also be mutated. Additionally, 
previous studies have suggested that C-peptide glutamate residues are 
important for insulin folding [60]. This makes it difficult to attribute any effects of 
C-peptide mutations on the secretion of biologically active insulin to a specific 
misfolding mechanism. On the other hand, as demonstrated in Paper VIII, the 
detection of amyloid microdeposits requires targeted and meticulous 
investigations, and it is not impossible that C-peptide-related insulin aggregation 
has in fact gone unnoticed. Therefore, further studies on the subject are needed. 
2. The high β-sheet propensity of SP-C can easily be abolished by exchange of its 
valine residues for leucines. Yet, evolutionary pressure has apparently not 
corrected this “design flaw”. Our results obtained from the proSP-C and Bri2 
BRICHOS domains propose that it might be more advantageous to develop a 
protein domain with anti-amyloid activity that can be installed in different 
functional settings instead of tuning the aggregation propensity in each 
amyloidogenic protein individually. However, whether BRICHOS domains really 
have a general anti-amyloid function similar to the proposed “amyloid 
scavenger” protease insulin degrading enzyme [143] remains to be investigated. 
3.  The assembly-controlling functions of spider silk protein C- and N-terminal 
domains show that the secondary structure of a stretch of >3000 residues can 
be controlled by two <130 residue-domains. It has been proposed that storage 
of MaSp proteins occurs in “micelle” form, with the folded terminal domains 
function analogous to the polar head groups in lipid micelles [138]. However, no 
direct evidence for this model has been presented yet. Therefore, our 
understanding of the assembly of spider silk from the soluble dope is incomplete 
until the structural arrangements of spidroins in the ampullate gland storage 
form has been described in more detail. 
 
The above points represent new points of departure in the journey towards 
understanding the biology of amyloid. Personally, I am positive that eventually answers 
to these and the many other remaining questions will hold the key to a targeted, 
efficient approach for tackling amyloid disease. This is the reason we conduct our 
investigations. 
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